ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1604

Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis

Peter Merkel1, Peter Baudy2, Donna Carstens2, Benjamin North3, Mahvish Danka3, Stephanie Roy3, Hanna Marshall3 and Geoffrey Chupp4, 1University of Pennsylvania, Philadelphia, PA, 2Respiratory & Immunology US Medical, AstraZeneca, Wilmington, 3IQVIA, Philadelphia, 4School of Medicine, Yale University, New Haven

Meeting: ACR Convergence 2024

Keywords: ANCA associated vasculitis, Diagnostic criteria, Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Vasculitis – ANCA-Associated Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis that can present indolently. This can lead to a delay in diagnosis and treatment. This study used machine learning to identify pre-diagnostic attributes of EGPA, estimate the prevalence of EGPA, and create a clinical decision screening tool to reduce time to diagnose EGPA.

Methods: Leveraging IQVIA’s United States medical and pharmacy claims data and laboratory results, ~2,800–4,000 patients were split into positive and negative cohorts. All patients were required to have a history of asthma or oral glucocorticoid use. Two cohort designs and decision tree models were developed to create a clinical decision screening tool: i) A rolling cross-section (RCS) model that used 2 years of training data and a gap of 0–6 months between end of source data and date of diagnosis in known medical history; ii) A non-RCS model that used ≥1 year of training data and the maximum possible data after January 2016, including claims data available directly before diagnosis.

Results: The positive predictive value of all models exceeded the baseline prevalence and incidence rates in the dataset (Figure 1). The RCS model estimated approximately 9,644–11,793 cases of EGPA. Key determinants within the models showed that eosinophilia, asthma, chronic sinusitis, multiple chest x-rays, skin biopsies, and multiple prescriptions of oral glucocorticoids were most predictive of a diagnosis of EGPA (Table 1). The first decision tree model uncovered four possible decision pathways for use within the clinical decision screening tool.

Conclusion: These results demonstrate that leveraging machine learning and claims data can improve the estimation of prevalence of EGPA in the United States and aid in arriving at an earlier diagnosis of EGPA. Up to 100 key events were identified by the model as pivotal in identifying patients with EGPA. The decision tree models may offer improved methods for research using electronic health records and claims data, and help health systems improve the care of patients with EGPA.

Supporting image 1

Figure 1. Non-rolling cross-section model (A) and pruned non-rolling cross-section model (B) for predicting a diagnosis of eosinophilic granulomatosis with polyangiitis

Supporting image 2

Table 1. Non-rolling cross-section and pruned non-rolling cross-section model features for predicting a diagnosis of eosinophilic granulomatosis with polyangiitis


Disclosures: P. Merkel: AbbVie/Abbott, 2, 5, Amgen, 2, 5, argenx, 2, AstraZeneca, 2, 5, Boehringer Ingelheim, 3, 5, Bristol Myers Squibb, 2, 5, Cabaletta, 2, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 5, Electra, 5, EMDSerano, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GSK, 2, 5, HiBio, 2, Immagene, 2, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Kyverna, 2, Magenta, 2, MiroBio, 2, Neutrolis, 2, Novartis, 2, NS Pharma, 2, Pfizer, 2, Q32, 2, 11, Regeneron, 2, Sanofi, 5, Sparrow, 2, 11, Takeda, 2, 5, Talaris, 2, UpToDate, 9, Visterra, 2; P. Baudy: AstraZeneca, 3, 11; D. Carstens: AstraZeneca, 3, 11; B. North: AstraZeneca, 12, Employee of IQVIA, which received funding from AstraZeneca to conduct this study.; M. Danka: AstraZeneca, 12, Employee of IQVIA, which received funding from AstraZeneca to conduct this study.; S. Roy: AstraZeneca, 12, Employee of IQVIA, which received funding from AstraZeneca to conduct this study.; H. Marshall: AstraZeneca, 12, Employee of IQVIA, which received funding from AstraZeneca to conduct this study.; G. Chupp: AstraZeneca, 6, Boehringer-Ingelheim, 6, Boston Scientific, 6, Circassia, 6, Genentech, 6, GlaxoSmithKline (GSK), 6, Regeneron Pharmaceuticals, 6, Sanofi–Genzyme, 6, Teva, 6.

To cite this abstract in AMA style:

Merkel P, Baudy P, Carstens D, North B, Danka M, Roy S, Marshall H, Chupp G. Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/utilizing-machine-learning-with-claims-data-to-diagnose-and-quantify-the-prevalence-of-eosinophilic-granulomatosis-with-polyangiitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utilizing-machine-learning-with-claims-data-to-diagnose-and-quantify-the-prevalence-of-eosinophilic-granulomatosis-with-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology